Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Total Current Liabilities (2024 - 2026)

Maze Therapeutics' Total Current Liabilities history spans 3 years, with the latest figure at $21.2 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities rose 14.07% to $21.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $21.2 million, a 14.07% increase, with the full-year FY2025 number at $22.6 million, up 9.11% from a year prior.
  • Total Current Liabilities hit $21.2 million in Q1 2026 for Maze Therapeutics, down from $22.6 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for MAZE hit a ceiling of $22.6 million in Q4 2025 and a floor of $18.6 million in Q1 2025.
  • Historically, Total Current Liabilities has averaged $20.8 million across 3 years, with a median of $21.0 million in 2024.
  • Biggest five-year swings in Total Current Liabilities: rose 9.11% in 2025 and later rose 14.07% in 2026.
  • Tracing MAZE's Total Current Liabilities over 3 years: stood at $20.7 million in 2024, then increased by 9.11% to $22.6 million in 2025, then dropped by 5.85% to $21.2 million in 2026.
  • Business Quant data shows Total Current Liabilities for MAZE at $21.2 million in Q1 2026, $22.6 million in Q4 2025, and $22.1 million in Q3 2025.